IL6 and prostate carcinoma: Thus, during the progression of prostate cancer to the hormone refractory phenotype, IL-6 undergoes a functional transition from paracrine growth inhibitor to autocrine growth stimulator (Hobisch et al, 1998; Deeble et al, 2001).